Publication
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Journal Paper/Review - Nov 17, 2021
Schneeweiss Andreas, Blohmer Jens-Uwe, Fasching Peter A, Solbach Christine, Schmutzler Rita K, Huober Jens, Rhiem Kerstin, Nekljudova Valentina, Lübbe Kristina, Loibl Sibylle, Jackisch Christian, Untch Michael, Link Theresa, Michel Laura L, Möbus Volker, Tesch Hans, Klare Peter, Hahnen Eric, Denkert Carsten, Kast Karin, Pohl-Rescigno Esther, Hanusch Claus, GBG and AGO-B
Schneeweiss, Andreas
77
0
Michel, Laura L
3
0
Möbus, Volker
20
0
Tesch, Hans
47
0
Klare, Peter
8
0
Hahnen, Eric
4
0
Denkert, Carsten
49
0
Kast, Karin
3
0
Pohl-Rescigno, Esther
1
0
Hanusch, Claus
42
0
Link, Theresa
8
0
Untch, Michael
88
0
Jackisch, Christian
69
0
Blohmer, Jens-Uwe
48
0
Fasching, Peter A
74
0
Solbach, Christine
24
0
Schmutzler, Rita K
2
0
Huober, Jens
chief physicianBrustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I
298
12
Rhiem, Kerstin
22
0
Nekljudova, Valentina
35
0